The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases such as cancer.
Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase
作者:Jeffrey Y. Melamed、Melissa S. Egbertson、Sandor Varga、Joseph P. Vacca、Greg Moyer、Lori Gabryelski、Peter J. Felock、Kara A. Stillmock、Marc V. Witmer、William Schleif、Daria J. Hazuda、Yvonne Leonard、Lixia Jin、Joan D. Ellis、Steven D. Young
DOI:10.1016/j.bmcl.2008.08.038
日期:2008.10
HIV-1 integrase catalyzes the insertion of viral DNA into the genome of the host cell. Integrase inhibitor N-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide selectively inhibits the strand transfer process of integration. 4-Substituted pyrrolidinones possessing various groups on the pyrrolidinone nitrogen were introduced at the 5-position of the naphthyridine scaffold. These analogs exhibit excellent activity against viral replication in a cell-based assay. The preparation of these compounds was enabled by a three-step, two-pot reaction sequence from a common butenolide intermediate. (c) 2008 Elsevier Ltd. All rights reserved.